Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Risk | Very High | Very High |
Rating | 3.0 | 4.0 |
Min SIP Amount | ₹100 | ₹100 |
Expense Ratio | 2.33 | 2.2 |
NAV | ₹18.35 | ₹100.22 |
Fund Started | 02 Sep 2021 | 25 Mar 1997 |
Fund Size | ₹785.25 Cr | ₹1072.74 Cr |
Exit Load | Exit Load for units in excess of 10% of the investment,1% will be charged for redemption within 12 months. | Exit load of 1%, if redeemed within 30 days. |
Risk
Rating
Min SIP Amount
Expense Ratio
NAV
Fund Started
Fund Size
Exit Load
1 Year | 29.32% | 26.39% |
3 Year | 21.44% | 25.14% |
5 Year | - | 24.37% |
1 Year
3 Year
5 Year
Equity | 87.67% | 99.31% |
Cash | 1.57% | 0.69% |
Equity
Cash
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
---|---|
HDFC Bank Ltd. | 5.70% |
ICICI Bank Ltd. | 5.09% |
Infosys Ltd. | 3.54% |
Reliance Industries Ltd. | 3.04% |
Bharti Airtel Ltd. | 3.03% |
Mahindra & Mahindra Ltd. | 2.68% |
Anant Raj Ltd. | 2.61% |
State Bank of India | 2.41% |
Larsen & Toubro Ltd. | 2.36% |
NTPC Ltd. | 2.22% |
Name | Assets |
---|---|
HDFC Bank Ltd. | 7.21% |
Infosys Ltd. | 4.57% |
ICICI Bank Ltd. | 4.12% |
Dr. Reddy's Laboratories Ltd. | 3.14% |
State Bank of India | 2.74% |
NTPC Ltd. | 2.64% |
REC Ltd. | 2.49% |
Tech Mahindra Ltd. | 2.23% |
Amber Enterprises India Ltd. | 2.16% |
Suven Pharmaceuticals Ltd. | 2.07% |
Name | Vinayak Jayanath | Satish Ramanathan |
Start Date | 17 Jan 2023 | 01 Oct 2024 |
Name
Start Date
Description | The schemes seeks to generate consistent long-term capital appreciation by investing predominantly in equity and equity related securities by following value investing strategy. | The scheme aims to provide long term capital growth by investing primarily in a well-diversified portfolio of undervalued securities. |
Launch Date | 02 Sep 2021 | 25 Mar 1997 |
Description
Launch Date